相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors
Ee Lyn Lim et al.
JCI INSIGHT (2018)
FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance
Jeffrey A. Bluestone
JOURNAL OF IMMUNOLOGY (2017)
Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Rasha Abu Eid et al.
CANCER RESEARCH (2017)
Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy
Shamim Ahmad et al.
CANCER RESEARCH (2017)
Human regulatory T cells control TCR signaling and susceptibility to suppression in CD4+ T cells
Stalin Chellappa et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With First-Line Idelalisib Plus Rituximab After Cessation of Treatment for Toxicity
Philip A. Thompson et al.
CANCER (2016)
AKT isoforms modulate Th1-like Treg generation and function in human autoimmune disease
Alexandra Kitz et al.
EMBO REPORTS (2016)
Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections
Donald T. Gracias et al.
JOURNAL OF IMMUNOLOGY (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
PI3Kδ and primary immunodeficiencies
Carrie L. Lucas et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang et al.
CLINICAL CANCER RESEARCH (2015)
The interplay of effector and regulatory T cells in cancer
Rahul Roychoudhuri et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
PI3K inhibitors in inflammation, autoimmunity and cancer
Anne-Katrien Stark et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes
Verity Q. Pearce et al.
JOURNAL OF IMMUNOLOGY (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses
Sharad Shrestha et al.
NATURE IMMUNOLOGY (2015)
Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability
Alexandria Huynh et al.
NATURE IMMUNOLOGY (2015)
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
Bin Shang et al.
SCIENTIFIC REPORTS (2015)
Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation
Jean-Marc Doisne et al.
CELL REPORTS (2015)
Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Joseph G. Crompton et al.
CANCER RESEARCH (2015)
Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool
J. Christoph Vahl et al.
IMMUNITY (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Continuous requirement for the TCR in regulatory T cell function
Andrew G. Levine et al.
NATURE IMMUNOLOGY (2014)
Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
Rasha Abu-Eid et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Klaus Okkenhaug
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Modulating T regulatory cells in cancer: how close are we?
Ashish Banerjee et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
An obligate cell-intrinsic function for CD28 in Tregs
Ruan Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer
Harald von Boehmer et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature
Ronald J. deLeeuw et al.
CLINICAL CANCER RESEARCH (2012)
Naturally occurring regulatory T cells: markers, mechanisms, and manipulation
Klaus G. Schmetterer et al.
FASEB JOURNAL (2012)
Does the PI3K pathway promote or antagonize regulatory T cell development and function?
Dalya R. Soond et al.
FRONTIERS IN IMMUNOLOGY (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells
Xin Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
T Cell-Signaling Network Analysis Reveals Distinct Differences between CD28 and CD2 Costimulation Responses in Various Subsets and in the MAPK Pathway between Resting and Activated Regulatory T Cells
Maria Elisabeth Kalland et al.
JOURNAL OF IMMUNOLOGY (2011)
The PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
Daniel T. Patton et al.
PLOS ONE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans
Dalya R. Soond et al.
BLOOD (2010)
T regulatory cells in cancer: recent advances and therapeutic potential
Eyad Elkord et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction
Julia Rolf et al.
JOURNAL OF IMMUNOLOGY (2010)
B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
Jonathan M. Irish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
FOXP3+ regulatory T cells in the human immune system
Shimon Sakaguchi et al.
NATURE REVIEWS IMMUNOLOGY (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
MAPK, Phosphatidylinositol 3-Kinase, and Mammalian Target of Rapamycin Pathways Converge at the Level of Ribosomal Protein S6 Phosphorylation to Control Metabolic Signaling in CD8 T Cells
Robert J. Salmond et al.
JOURNAL OF IMMUNOLOGY (2009)
The p110δ Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells
Dong Liu et al.
JOURNAL OF IMMUNOLOGY (2009)
Altered activation of AKT is required for the suppressive function of human CD4+ CD25+ T regulatory cells
Natasha K. Crellin et al.
BLOOD (2007)
Role of the phosphoinositide 3-kinase p110δ in generation of type 2 cytokine responses and allergic airway inflammation
Baher F. Nashed et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Cutting edge:: The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells
Daniel T. Patton et al.
JOURNAL OF IMMUNOLOGY (2006)
The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells
Klaus Okkenhaug et al.
JOURNAL OF IMMUNOLOGY (2006)
PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ Tregs
Patrick T. Walsh et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
CARMA1 is required for Akt-mediated NF-κB activation in T cells
P Narayan et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells
SJ Bensinger et al.
JOURNAL OF IMMUNOLOGY (2004)
分享论文
